UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 316

Sortiert nach

Early Off-Study Experience of Chimeric Antigen Receptor T Cells in Aggressive Lymphoma: Closer to a Real-World Setting

Journal of clinical oncology, 2020-09, Vol.38 (27), p.3085-3087

2020

Volltextzugriff (PDF)

Impact of Age on Poly(ADP-Ribose) Polymerase Inhibitor (PARPi)-Induced Lymphopenia: A Scoping Review of the Literature and Internal Analysis of a Retrospective Database

Drugs & aging, 2023-05, Vol.40 (5), p.397-405

2023

Volltextzugriff (PDF)

Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation

The American journal of surgical pathology, 2022-01, Vol.46 (1), p.58

2022

Volltextzugriff (PDF)

Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma

Blood, 2018-06, Vol.131 (25), p.2856-2859

2018

Volltextzugriff (PDF)

Development of Vitreoretinal Lymphoma in a Patient with Sarcoid Uveitis

Ocular immunology and inflammation, 2020-05, Vol.28 (4), p.647-650

2020

Volltextzugriff (PDF)

Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts

Journal of clinical oncology, 2019-01, Vol.37 (2), p.144-152

2019

Volltextzugriff (PDF)

Early event status informs subsequent outcome in newly diagnosed follicular lymphoma

American journal of hematology, 2016-11, Vol.91 (11), p.1096-1101

2016

Volltextzugriff (PDF)

Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

Journal of clinical oncology, 2014-04, Vol.32 (10), p.1066-1073

2014

Volltextzugriff (PDF)

Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas

Clinical cancer research, 2012-10, Vol.18 (19), p.5203-5211

2012

Volltextzugriff (PDF)

Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma

Blood, 2017-05, Vol.129 (18), p.2471-2478

2017

Volltextzugriff (PDF)

Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma

Blood, 2014-04, Vol.123 (17), p.2740-2742

2014

Volltextzugriff (PDF)

Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514)

European journal of cancer (1990), 2023-08, Vol.189, p.112909-112909, Article 112909

2023

Volltextzugriff (PDF)

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL)

Journal of clinical oncology, 2018-09, Vol.36 (25), p.2593-2602

2018

Volltextzugriff (PDF)

CAR-T cells, from principle to clinical applications

Bulletin du cancer, 2021-10, Vol.108 (10), p.S4-S17

2021

Volltextzugriff (PDF)

Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study

Haematologica (Roma), 2023-03, Vol.108 (3), p.822

2023

Volltextzugriff (PDF)

Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation

European journal of cancer (1990), 2019-07, Vol.115, p.47-56

2019

Volltextzugriff (PDF)

Pneumonitis following immunochemotherapy with rituximab: a new well-designed retrospective study to better assess the risks

Leukemia & lymphoma, 2015-06, Vol.56 (6), p.1577-1578

Ghesquières, Hervé

2015

Volltextzugriff (PDF)

Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

Nature (London), 2024-01, Vol.625 (7996), p.778-787

2024

Volltextzugriff (PDF)

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma

Expert opinion on biological therapy, 2021-04, Vol.21 (4), p.455-463

2021

Volltextzugriff (PDF)

1 – 25 von 316

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(311)
Mit Volltextzugriff
(301)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(154)
Life Sciences & Biomedicine
(152)
Humans
(118)
Hematology
(94)
Oncology
(81)
Life Sciences
(79)
Female
(71)
Male
(70)
Middle Aged
(65)
Aged
(60)
Adult
(56)
Lymphoma
(53)
Aged, 80 And Over
(36)
Cancer
(36)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(32)
Retrospective Studies
(32)
Chemotherapy
(30)
Patients
(30)
Treatment Outcome
(30)
Prognosis
(26)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(109)
Journal Of Clinical Oncology
(23)
Leukemia & Lymphoma
(14)
Clinical Lymphoma, Myeloma And Leukemia
(13)
Hematological Oncology
(12)
American Journal Of Hematology
(9)
British Journal Of Haematology
(9)
Cancers
(9)
Haematologica
(8)
Blood Advances
(5)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Early Off-Study Experience of Chimeric Antigen Receptor T Cells in Aggressive Lymphoma: Closer to a Real-World Setting

Impact of Age on Poly(ADP-Ribose) Polymerase Inhibitor (PARPi)-Induced Lymphopenia: A Scoping Review of the Literature and Internal Analysis of a Retrospective Database

Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation

Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma

Development of Vitreoretinal Lymphoma in a Patient with Sarcoid Uveitis

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study

Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts

Early event status informs subsequent outcome in newly diagnosed follicular lymphoma

Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas

Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study

Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL)

CAR-T cells, from principle to clinical applications

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study

Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation

Pneumonitis following immunochemotherapy with rituximab: a new well-designed retrospective study to better assess the risks

Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma

Suchergebnisse filtern